Data regarding BCMA expression on other B-cell malignancies are scarce, and for CLL, DLBCL, follicular lymphoma, and MCL conflicting reports have been published (17, 24–27), which complicated the question whether BCMA is a feasible target in these diseases. This evidence concerns the gene TNFRSF17 and follicular lymphoma.